QurAlis Corporation
- Biotech or pharma, therapeutic R&D
QurAlis, backed by leading investors, is a clinical-stage biotech company developing RNA-targeted therapies for genetically defined neurodegenerative diseases. Founded by scientific leaders from Harvard Medical School, QurAlis is advancing precision medicine programs in ALS and FTD in the clinic. With strong external validation through a licensing agreement with Eli Lilly for its soon-to-be clinical-stage UNC13A-targeted ALS program, the company leverages its proprietary FlexASO® platform to develop splice-switching antisense oligonucleotides, with the goal of delivering first- and best-in-class disease-modifying therapies. Its growing pipeline includes additional programs in progressive supranuclear palsy (PSP) and Fragile X syndrome.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}